Mammalian animal models for Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 19, Issue 4, 2009, Pages 241-249

  Willmann, Raffaella ^a   Possekel, Stefanie ^b   Dubach Powell, Judith ^b   Meier, Thomas ^b   Ruegg, Markus A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Santhera Pharmaceuticals   (Switzerland)

Author keywords

Animal models; Cat; Dog; Duchenne muscular dystrophy; GRMD; mdx; Mouse

Indexed keywords

CREATINE KINASE; DYSTROPHIN; HYDROXYPROLINE; INTEGRIN; MYOD PROTEIN;

C57BL MOUSE; CALCIUM CELL LEVEL; CLINICAL FEATURE; DISEASE COURSE; DISEASE MODEL; DRUG RESEARCH; DRUG SCREENING; DUCHENNE MUSCULAR DYSTROPHY; GENE DELETION; GENE MUTATION; HISTOLOGY; HUMAN; MAMMAL; MOLECULAR MECHANICS; MUSCLE STRENGTH; NEUROMUSCULAR DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CATS; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; GENE KNOCKOUT TECHNIQUES; HUMANS; MAMMALS; MICE; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; SPECIES SPECIFICITY;

EID: 63749096532     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2008.11.015     Document Type: Review

References (87)

1. Grounds M.D., Radley H.G., Lynch G.S., Nagaraju K., and De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 31 1 (2008) 1-19
2. Ervasti J.M. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta 1772 2 (2007) 108-117
3. Gailly P. New aspects of calcium signaling in skeletal muscle cells: implications in Duchenne muscular dystrophy. Biochim Biophys Acta 1600 1-2 (2002) 38-44
4. Koenig M., Beggs A.H., Moyer M., et al. The molecular basis for Duchenne versus becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45 4 (1989) 498-506
5. Hoffman E.P., Brown Jr. R.H., and Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51 6 (1987) 919-928
6. Bulfield G., Siller W.G., Wight P.A., and Moore K.J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 81 4 (1984) 1189-1192
7. Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 2007.
8. McGeachie J.K., Grounds M.D., Partridge T.A., and Morgan J.E. Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies. J Neurol Sci 119 2 (1993) 169-179
9. Grounds M.D., and Torrisi J. Anti-TNFalpha (remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 18 6 (2004) 676-682
10. Messina S., Bitto A., Aguennouz M., et al. Nuclear factor kappa-b blockade reduces skeletal muscle degeneration and enhances muscle function in mdx mice. Exp Neurol 198 1 (2006) 234-241
11. Spencer M.J., and Tidball J.G. Calpain translocation during muscle fiber necrosis and regeneration in dystrophin-deficient mice. Exp Cell Res 226 2 (1996) 264-272
12. Lefaucheur J.P., Pastoret C., and Sebille A. Phenotype of dystrophinopathy in old mdx mice. Anat Rec 242 1 (1995) 70-76
13. Stedman H.H., Sweeney H.L., Shrager J.B., et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352 6335 (1991) 536-539
14. Connolly A.M., Keeling R.M., Mehta S., Pestronk A., and Sanes J.R. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord 11 8 (2001) 703-712
15. Rolland J.F., De Luca A., Burdi R., Andreetta F., Confalonieri P., and Conte Camerino D. Overactivity of exercise-sensitive cation channels and their impaired modulation by igf-1 in mdx native muscle fibers: beneficial effect of pentoxifylline. Neurobiol Dis 24 3 (2006) 466-474
16. Raymackers J.M., Debaix H., Colson-Van Schoor M., et al. Consequence of parvalbumin deficiency in the mdx mouse: histological, biochemical and mechanical phenotype of a new double mutant. Neuromuscul Disord 13 5 (2003) 376-387
17. Burdi R., Didonna M.P., Pignol B., et al. First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, bn 82270, acting as calpain-inhibitor and anti-oxidant. Neuromuscul Disord 16 4 (2006) 237-248
18. Fraysse B., Liantonio A., Cetrone M., et al. The alteration of calcium homeostasis in adult dystrophic mdx muscle fibers is worsened by a chronic exercise in vivo. Neurobiol Dis 17 2 (2004) 144-154
19. Deconinck N., Rafael J.A., Beckers-Bleukx G., et al. Consequences of the combined deficiency in dystrophin and utrophin on the mechanical properties and myosin composition of some limb and respiratory muscles of the mouse. Neuromuscul Disord 8 6 (1998) 362-370
20. Lynch G.S., Cuffe S.A., Plant D.R., and Gregorevic P. Igf-i treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. Neuromuscul Disord 11 3 (2001) 260-268
21. Louis M., Raymackers J.M., Debaix H., Lebacq J., and Francaux M. Effect of creatine supplementation on skeletal muscle of mdx mice. Muscle Nerve 29 5 (2004) 687-692
22. Laws N., and Hoey A. Progression of kyphosis in mdx mice. J Appl Physiol 97 5 (2004) 1970-1977
23. Gayraud J., Matecki S., Hnia K., et al. Ventilation during air breathing and in response to hypercapnia in 5- and 16-month-old mdx and c57 mice. J Muscle Res Cell Motil 28 1 (2007) 29-37
24. Quinlan J.G., Hahn H.S., Wong B.L., Lorenz J.N., Wenisch A.S., and Levin L.S. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 14 8-9 (2004) 491-496
25. Bia B.L., Cassidy P.J., Young M.E., et al. Decreased myocardial nnos, increased inos and abnormal ecgs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 31 10 (1999) 1857-1862
26. Wehling-Henricks M., Jordan M.C., Roos K.P., Deng B., and Tidball J.G. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 14 14 (2005) 1921-1933
27. Spurney C.F., Knoblach S., Pistilli E.E., Nagaraju K., Martin G.R., and Hoffman E.P. Dystrophin-deficient cardiomyopathy in mouse: expression of nox4 and lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord 18 5 (2008) 371-381
28. Van Erp C., Irwin N.G., and Hoey A.J. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 34 3 (2006) 327-334
29. Cohn R.D., Liang H.Y., Shetty R., Abraham T., and Wagner K.R. Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscul Disord 17 4 (2007) 290-296
30. Buyse G.M., Van der Mieren G., Erb M., et al. Long-term blinded placebo-controlled study of snt-mc17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. Eur Heart J. (2008)
31. De Backer F., Vandebrouck C., Gailly P., and Gillis J.M. Long-term study of Ca(2+) homeostasis and of survival in collagenase-isolated muscle fibres from normal and mdx mice. J Physiol 542 Pt 3 (2002) 855-865
32. Gailly P., Hermans E., Octave J.N., and Gillis J.M. Specific increase of genetic expression of parvalbumin in fast skeletal muscles of mdx mice. FEBS Lett 326 1-3 (1993) 272-274
33. Sano M., Yokota T., Endo T., and Tsukagoshi H. A developmental change in the content of parvalbumin in normal and dystrophic mouse (mdx) muscle. J Neurol Sci 97 2-3 (1990) 261-272
34. + channels. Proc Natl Acad Sci USA 97 9 (2000) 4950-4955
35. Robert V., Massimino M.L., Tosello V., et al. Alteration in calcium handling at the subcellular level in mdx myotubes. J Biol Chem 276 7 (2001) 4647-4651
36. Liberona J.L., Powell J.A., Shenoi S., Petherbridge L., Caviedes R., and Jaimovich E. Differences in both inositol 1,4,5-trisphosphate mass and inositol 1,4,5-trisphosphate receptors between normal and dystrophic skeletal muscle cell lines. Muscle Nerve 21 7 (1998) 902-909
37. Granchelli J.A., Pollina C., and Hudecki M.S. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 10 4-5 (2000) 235-239
38. Vilquin J.T., Brussee V., Asselin I., Kinoshita I., Gingras M., and Tremblay J.P. Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise. Muscle Nerve 21 5 (1998) 567-576
39. Hodgetts S., Radley H., Davies M., and Grounds M.D. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with etanercept in mdx mice. Neuromuscul Disord 16 9-10 (2006) 591-602
40. De Luca A., Nico B., Liantonio A., et al. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol 166 2 (2005) 477-489
41. Nakamura A., Yoshida K., Takeda S., Dohi N., and Ikeda S. Progression of dystrophic features and activation of mitogen-activated protein kinases and calcineurin by physical exercise, in hearts of mdx mice. FEBS Lett 520 1-3 (2002) 18-24
42. Chapman V.M., Miller D.R., Armstrong D., and Caskey C.T. Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci USA 86 4 (1989) 1292-1296
43. Cox G.A., Phelps S.F., Chapman V.M., and Chamberlain J.S. New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nat Genet 4 1 (1993) 87-93
44. Araki E., Nakamura K., Nakao K., et al. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Biochem Biophys Res Commun 238 2 (1997) 492-497
45. Deconinck A.E., Rafael J.A., Skinner J.A., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90 4 (1997) 717-727
46. Grady R.M., Teng H., Nichol M.C., Cunningham J.C., Wilkinson R.S., and Sanes J.R. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90 4 (1997) 729-738
47. Megeney L.A., Kablar B., Garrett K., Anderson J.E., and Rudnicki M.A. Myod is required for myogenic stem cell function in adult skeletal muscle. Genes Dev 10 10 (1996) 1173-1183
48. Megeney L.A., Kablar B., Perry R.L., Ying C., May L., and Rudnicki M.A. Severe cardiomyopathy in mice lacking dystrophin and myod. Proc Natl Acad Sci USA 96 1 (1999) 220-225
49. Grady R.M., Grange R.W., Lau K.S., et al. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1 4 (1999) 215-220
50. Mayer U. Integrins: redundant or important players in skeletal muscle?. J Biol Chem 278 17 (2003) 14587-14590
51. Guo C., Willem M., Werner A., et al. Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet 15 6 (2006) 989-998
52. Burkin D.J., Wallace G.Q., Nicol K.J., Kaufman D.J., and Kaufman S.J. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol 152 6 (2001) 1207-1218
53. Sharp N.J., Kornegay J.N., Van Camp S.D., et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13 1 (1992) 115-121
54. Ambrosio C.E., Valadares M.C., Zucconi E., et al. Ringo, a golden retriever muscular dystrophy (grmd) dog with absent dystrophin but normal strength. Neuromuscul Disord (2008)
55. Valentine BA, Cooper BJ, de Lahunta A, O'Quinn R, Blue JT. Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci 1988;88(1-3):69-81.
56. Kornegay J.N., Cundiff D.D., Bogan D.J., Bogan J.R., and Okamura C.S. The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy. Neuromuscul Disord 13 6 (2003) 493-500
57. Moise N.S., Valentine B.A., Brown C.A., et al. Duchenne's cardiomyopathy in a canine model: electrocardiographic and echocardiographic studies. J Am Coll Cardiol 17 3 (1991) 812-820
58. Chetboul V., Escriou C., Tessier D., et al. Tissue Doppler imaging detects early asymptomatic myocardial abnormalities in a dog model of Duchenne's cardiomyopathy. Eur Heart J 25 21 (2004) 1934-1939
59. Thibaud J.L., Monnet A., Bertoldi D., Barthelemy I., Blot S., and Carlier P.G. Characterization of dystrophic muscle in golden retriever muscular dystrophy dogs by nuclear magnetic resonance imaging. Neuromuscul Disord 17 7 (2007) 575-584
60. Shimatsu Y., Katagiri K., Furuta T., et al. Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 52 2 (2003) 93-97
61. Shimatsu Y., Yoshimura M., Yuasa K., et al. Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 24 2 (2005) 145-154
62. Winand N.J., Edwards M., Pradhan D., Berian C.A., and Cooper B.J. Deletion of the dystrophin muscle promoter in feline muscular dystrophy. Neuromuscul Disord 4 5-6 (1994) 433-445
63. Gaschen F.P., Hoffman E.P., Gorospe J.R., et al. Dystrophin deficiency causes lethal muscle hypertrophy in cats. J Neurol Sci 110 1-2 (1992) 149-159
64. Gaschen L., Lang J., Lin S., et al. Cardiomyopathy in dystrophin-deficient hypertrophic feline muscular dystrophy. J Vet Intern Med 13 4 (1999) 346-356
65. Fisher R., Tinsley J.M., Phelps S.R., et al. Non-toxic ubiquitous over-expression of utrophin in the mdx mouse. Neuromuscul Disord 11 8 (2001) 713-721
66. Gaedigk R., Law D.J., Fitzgerald-Gustafson K.M., et al. Improvement in survival and muscle function in an mdx/utrn(-/-) double mutant mouse using a human retinal dystrophin transgene. Neuromuscul Disord 16 3 (2006) 192-203
67. Kornegay J.N., Bogan D.J., Bogan J.R., et al. Contraction force generated by tarsal joint flexion and extension in dogs with golden retriever muscular dystrophy. J Neurol Sci 166 2 (1999) 115-121
68. Vrbova G. Comment on Connolly am, et al. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice (Neuromuscul Disord 2001;11:703-12). Neuromuscul Disord 2002;12:608-9.
69. Keeling R.M., Golumbek P.T., Streif E.M., and Connolly A.M. Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 35 1 (2007) 43-48
70. Pierno S., Nico B., Burdi R., et al. Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol Appl Neurobiol 33 3 (2007) 344-359
71. Kornegay J.N., Sharp N.J., Bogan D.J., Van Camp S.D., Metcalf J.R., and Schueler R.O. Contraction tension and kinetics of the peroneus longus muscle in golden retriever muscular dystrophy. J Neurol Sci 123 1-2 (1994) 100-107
72. Bogdanovich S., Krag T.O., Barton E.R., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 6914 (2002) 418-421
73. Yue Y., Liu M., and Duan D. C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. Mol Ther 14 1 (2006) 79-87
74. Anderson J.E., Bressler B.H., and Ovalle W.K. Functional regeneration in the hindlimb skeletal muscle of the mdx mouse. J Muscle Res Cell Motil 9 6 (1988) 499-515
75. Morrison J., Palmer D.B., Cobbold S., Partridge T., and Bou-Gharios G. Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse. Am J Pathol 166 6 (2005) 1701-1710
76. Gillis J.M. Membrane abnormalities and ca homeostasis in muscles of the mdx mouse, an animal model of the Duchenne muscular dystrophy: a review. Acta Physiol Scand 156 3 (1996) 397-406
77. Wang X., Weisleder N., Collet C., et al. Uncontrolled calcium sparks act as a dystrophic signal for mammalian skeletal muscle. Nat Cell Biol 7 5 (2005) 525-530
78. Gosselin L.E., Barkley J.E., Spencer M.J., McCormick K.M., and Farkas G.A. Ventilatory dysfunction in mdx mice: impact of tumor necrosis factor-alpha deletion. Muscle Nerve 28 3 (2003) 336-343
79. Briguet A., Courdier-Fruh I., Foster M., Meier T., and Magyar J.P. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord 14 10 (2004) 675-682
80. Tinsley J., Deconinck N., Fisher R., et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4 12 (1998) 1441-1444
81. Gillis J-M. The functional consequences of dystrophin deficiency in skeletal muscles. In: Uversky VN, Fink A, editors. Protein misfolding, aggregation, and conformational diseases. New York: Springer Science; 2007. p. 409-33.
82. Wakefield P.M., Tinsley J.M., Wood M.J., Gilbert R., Karpati G., and Davies K.E. Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene. Gene Ther 7 3 (2000) 201-204
83. Rafael J.A., Tinsley J.M., Potter A.C., Deconinck A.E., and Davies K.E. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet 19 1 (1998) 79-82
84. Woo M., Tanabe Y., Ishii H., Nonaka I., Yokoyama M., and Esaki K. Muscle fiber growth and necrosis in dystrophic muscles: a comparative study between dy and mdx mice. J Neurol Sci 82 1-3 (1987) 111-122
85. Janssen P.M., Hiranandani N., Mays T.A., and Rafael-Fortney J.A. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 289 6 (2005) H2373-H2378
86. Valentine BA, Cummings JF, Cooper BJ. Development of Duchenne-type cardiomyopathy. Morphologic studies in a canine model. Am J Pathol 1989;135(4):671-8.
87. Blake D.J., and Kroger S. The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle?. Trends Neurosci 23 3 (2000) 92-99